Recurrent Infection of Continuous Subcutaneous Insulin Infusion Sites With <i>Mycobacterium fortuitum</i>

Boychuk, Lesia R; Kirkland, P.

doi:10.2337/diacare.18.9.1284

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,3,4 There are multiple reports of infection after trauma and surgical or other procedures, including acupuncture, 5 liposuction, 6-8 silicone injection, 9 breast implantation, [10][11][12] intravenous catheter use, 13 dermatologic surgery, 14,15 pedicures, [16][17][18] exposure to prosthetic material, 19 pacemaker placement, 20 and subcutaneous injections. [21][22][23][24][25] Pulmonary disease due to M fortuitum has been described following hot tub use. 26 Although the spectrum and features of clinical disease due to M chelonae have been described, 3 no reports have directly compared the clinical features of skin and soft tissue infections due to M chelonae, M abscessus, and M fortuitum, to our knowledge.…”

mentioning

confidence: 99%

Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria

Uslan¹,

Kowalski²,

Wengenack³

et al. 2006

Arch Dermatol

182

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria

Uslan¹,

Kowalski²,

Wengenack³

et al. 2006

Arch Dermatol

182

View full text Add to dashboard Cite

show abstract

“…There have been two reports of CSII injection sites becoming infected with unusual organisms such as Mycobacterium fortuitum 58,59 and one set of authors wondered if the risk of infection with organisms found in soil and water might be increased because users could bathe and swim with some devices. 59 The earlier reports nevertheless seem to have given rise to a widespread belief in the UK that CSII is unsafe.…”

mentioning

confidence: 99%

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Colquitt¹,

Green²,

Sidhu³

et al. 2004

Health Technol Assess

106

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts.Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then...

show abstract

“…This failure highlights the importance of surgical drainage combined with an appropriate duration of antimicrobial therapy in achieving a cure (2,5). We opted for a combination antimicrobial therapy, which is often used in the treatment of infections due to other rapidly growing mycobacteria (7).…”

mentioning

confidence: 99%

Bursitis Due to Mycobacterium goodii , a Recently Described, Rapidly Growing Mycobacterium

Friedman

Sexton

2001

J Clin Microbiol

View full text Add to dashboard Cite

We report a case of olecranon bursitis due to Mycobacterium goodii in a 60-year-old man. Prior to recognition of his infection, he received intrabursal steroids and underwent olecranon bursectomy. His infection was cured with antimicrobial therapy consisting of doxycycline and ciprofloxacin. This case illustrates that previously unrecognized members of the Mycobacterium smegmatis group of mycobacteria have pathogenic potential. CASE REPORTIn January 1999, a 60-year-old man with a history of hypertension, osteoarthritis, type II diabetes mellitus, and benign monoclonal gemmopathy developed bursitis of his right olecranon without an obvious predisposing cause. Initial treatment included intrabursal steroid injections and a short empiric course of ciprofloxacin. Pain and swelling persisted, and a right olecranon bursectomy was performed on 26 July 1999. A Gram stain of a specimen of tissue from the operation showed rare white blood cells but no organisms; pathologic examination of the same tissue revealed fibroadipose tissue with acute and chronic inflammation and occasional multinucleate giant cells.Postoperation the patient developed persistent purulent drainage from his wound with associated erythema in the incisional margins. Five weeks postoperation, fluid had reaccumulated in his bursal sac and an aspirate was performed. A Gram stain of the aspirated fluid once again revealed white blood cells but no organisms. However, a smear for acid-fast bacilli revealed organisms consistent with mycobacteria. Concurrently, final results for the operative specimen analyzed by the University of Texas by a PCR technique showed that the causative organism was Mycobacterium goodii. Bacterial culture of the operative specimen revealed gram-positive and acid-fast organisms that grew on sheep blood agar. After subculture onto Middlebrook media, growth of smooth nonpigmented colonies was noted within 3 days. This rapidly growing mycobacterium was sent to the University of Texas at Tyler for identification and susceptibility testing.The second bursal aspirate, in addition to a third bursal aspirate 8 weeks postoperation, yielded M. goodii on culture.On 15 September 1999, therapy with doxycycline (100 mg orally twice daily) and ciprofloxacin (500 mg orally twice daily) was commenced. Within 1 week of starting this therapy, the volume of daily drainage from the incision decreased. After 6 weeks of therapy, a follow-up examination showed no residual swelling, induration, or wound drainage. Therapy was continued through 2 December 1999. The patient remained free of all clinical signs of infection through 15 February 2000.Drug susceptibility testing (performed by Richard Wallace at the University of Texas Health Center in Tyler) revealed that the isolate was sensitive in vitro to amikacin, ciprofloxacin, doxycycline, imipenem, kanamycin, minocycline, ofloxacin, sulfamethoxazole, sulfisoxazole, tobramycin, and polymyxin B. The organism was intermediately susceptible to cefoxitin and resistant to clarithromycin.M. goodii was recognized a...

show abstract

Recurrent Infection of Continuous Subcutaneous Insulin Infusion Sites With Mycobacterium fortuitum

Cited by 16 publications

References 0 publications

Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria

Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Bursitis Due to Mycobacterium goodii , a Recently Described, Rapidly Growing Mycobacterium

Contact Info

Product

Resources

About